Cook Medical’s Zilver PTX Could Launch in Early 2012 and Double the Company’s Share of the Peripheral Vascular Stent Market

TORONTO--(BUSINESS WIRE)--According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, Cook Medical’s Zilver PTX drug-eluting stent is likely to be approved for use in the United States and launch in the first quarter of 2012. Last week, the Food and Drug Administration’s (FDA) Medical Devices Advisory Committee recommended Cook Medical’s Zilver PTX Drug-Eluting Stent for the treatment of peripheral artery disease (PAD) in the superficial femoral artery (SFA). Zilver PTX would be the first drug-eluting stent in the US indicated for the treatment of PAD in the SFA. According to proprietary MRG analysis, treatment of PAD in the femoropopliteal arteries will grow 12 percent per year through 2015, reaching 250,000 stent procedures annually.